Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

8.3%

1 terminated out of 12 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

9Total
Not Applicable (4)
Early P 1 (1)
P 2 (4)

Trial Status

Recruiting4
Unknown4
Active Not Recruiting3
Terminated1

Clinical Trials (12)

Showing 12 of 12 trials
NCT05281237Not ApplicableRecruiting

Avecure Flexible Microwave Ablation Probe For Lung Nodules

NCT03141359Phase 2Active Not RecruitingPrimary

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

NCT04991025Phase 2Recruiting

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

NCT04305613Active Not Recruiting

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy

NCT03290534Phase 2Recruiting

Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®

NCT03322072Not ApplicableActive Not Recruiting

Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating

NCT05258448Recruiting

COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)

NCT06060964Early Phase 1Unknown

Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management

NCT03984019Not ApplicableTerminated

Cardiac Changes After Stereotactic Radiotherapy for Early Stage NSCLC Cancer or Lung Metastasis

NCT04375566Unknown

Progressive Web App About Individualized Patient Decision Aid for NSCLC Stage I-II

NCT04970043Not ApplicableUnknownPrimary

Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment

NCT04108013Phase 2UnknownPrimary

A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC

Showing all 12 trials

Research Network

Activity Timeline